Literature DB >> 20685863

Circulating levels of soluble klotho and FGF23 in X-linked hypophosphatemia: circadian variance, effects of treatment, and relationship to parathyroid status.

Thomas O Carpenter1, Karl L Insogna, Jane H Zhang, Bruce Ellis, Sherril Nieman, Christine Simpson, Elizabeth Olear, Caren M Gundberg.   

Abstract

CONTEXT: Circulating fibroblast growth factor (FGF)-23 is variably elevated in individuals with X-linked hypophosphatemia (XLH), and klotho has recently been shown to effect renal phosphate handling, yet limited data are available on circulating FGF23 and klotho in XLH.
OBJECTIVE: The objective of the study was to characterize circulating FGF23 and klotho in XLH.
DESIGN: Children and adults with XLH withheld medication for 14 d. Fasting serum FGF23, PTH, klotho, phosphate, and 1,25 dihydroxyvitamin D were obtained. Treated adults were also sampled, and circadian sampling was performed in selected individuals.
SETTING: The study was conducted at a hospital research unit at an academic medical center. PATIENTS AND OTHER PARTICIPANTS: Participants included 23 individuals with XLH and eight controls.
INTERVENTIONS: There were no interventions. MAIN OUTCOME MEASURES: Serum klotho and FGF23 were measured.
RESULTS: FGF23 was greater in XLH than in controls and greater in treated XLH subjects compared with XLH subjects not receiving medical therapy. Children had higher klotho levels than adults, but values in XLH were similar to controls. A strong positive correlation between FGF23 and PTH was found in XLH subjects, whereas there was no relationship between these variables in controls. Circulating klotho, but not FGF23, has a diurnal pattern.
CONCLUSIONS: Serum klotho declines with age and demonstrates circadian variation but is normal in XLH. Serum FGF23 is similar in children and adults, is elevated in XLH, further increases with therapy, and demonstrates no diurnal variation. The direct relationship between FGF23 and PTH in subjects with XLH suggests that FGF23 regulation of PTH secretion is aberrant in this disorder.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20685863      PMCID: PMC2968736          DOI: 10.1210/jc.2010-0589

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  13 in total

1.  Oncogenic osteomalacia--a complex dance of factors.

Authors:  Thomas O Carpenter
Journal:  N Engl J Med       Date:  2003-04-24       Impact factor: 91.245

Review 2.  Evaluation of bone and mineral disorders.

Authors:  Laleh Ardeshirpour; David E C Cole; Thomas O Carpenter
Journal:  Pediatr Endocrinol Rev       Date:  2007-10

3.  Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23.

Authors:  K E White; G Carn; B Lorenz-Depiereux; A Benet-Pages; T M Strom; M J Econs
Journal:  Kidney Int       Date:  2001-12       Impact factor: 10.612

4.  Treatment of X-linked hypophosphatemia with calcitriol and phosphate increases circulating fibroblast growth factor 23 concentrations.

Authors:  Erik A Imel; Linda A DiMeglio; Siu L Hui; Thomas O Carpenter; Michael J Econs
Journal:  J Clin Endocrinol Metab       Date:  2010-02-15       Impact factor: 5.958

5.  Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia.

Authors:  Kenneth B Jonsson; Richard Zahradnik; Tobias Larsson; Kenneth E White; Toshitsugu Sugimoto; Yasuo Imanishi; Takehisa Yamamoto; Geeta Hampson; Hiroyuki Koshiyama; Osten Ljunggren; Koichi Oba; In Myung Yang; Akimitsu Miyauchi; Michael J Econs; Jeffrey Lavigne; Harald Jüppner
Journal:  N Engl J Med       Date:  2003-04-24       Impact factor: 91.245

6.  Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease.

Authors:  Orlando Gutierrez; Tamara Isakova; Eugene Rhee; Anand Shah; Julie Holmes; Gina Collerone; Harald Jüppner; Myles Wolf
Journal:  J Am Soc Nephrol       Date:  2005-05-25       Impact factor: 10.121

7.  Klotho converts canonical FGF receptor into a specific receptor for FGF23.

Authors:  Itaru Urakawa; Yuji Yamazaki; Takashi Shimada; Kousuke Iijima; Hisashi Hasegawa; Katsuya Okawa; Toshiro Fujita; Seiji Fukumoto; Takeyoshi Yamashita
Journal:  Nature       Date:  2006-10-29       Impact factor: 49.962

Review 8.  Fibroblast growth factor 23 acts on the parathyroid to decrease parathyroid hormone secretion.

Authors:  Hillel Galitzer; Iddo Ben-Dov; Vardit Lavi-Moshayoff; Tally Naveh-Many; Justin Silver
Journal:  Curr Opin Nephrol Hypertens       Date:  2008-07       Impact factor: 2.894

9.  Nocturnal hyperparathyroidism: a frequent feature of X-linked hypophosphatemia.

Authors:  T O Carpenter; M A Mitnick; A Ellison; C Smith; K L Insogna
Journal:  J Clin Endocrinol Metab       Date:  1994-06       Impact factor: 5.958

10.  A translocation causing increased alpha-klotho level results in hypophosphatemic rickets and hyperparathyroidism.

Authors:  Catherine A Brownstein; Felix Adler; Carol Nelson-Williams; Junko Iijima; Peining Li; Akihiro Imura; Yo-Ichi Nabeshima; Miguel Reyes-Mugica; Thomas O Carpenter; Richard P Lifton
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-28       Impact factor: 11.205

View more
  48 in total

1.  Uric acid and IGF1 as possible determinants of FGF23 metabolism in children with normal renal function.

Authors:  Justine Bacchetta; Pierre Cochat; Isidro B Salusky; Katherine Wesseling-Perry
Journal:  Pediatr Nephrol       Date:  2012-02-05       Impact factor: 3.714

Review 2.  Clinical practice: diagnostic approach to the rachitic child.

Authors:  Jaishen Rajah; Kebashni Thandrayen; John M Pettifor
Journal:  Eur J Pediatr       Date:  2011-07-21       Impact factor: 3.183

3.  Conventional Therapy in Adults With XLH Improves Dental Manifestations, But Not Enthesopathy.

Authors:  Michael J Econs
Journal:  J Clin Endocrinol Metab       Date:  2015-10       Impact factor: 5.958

Review 4.  [FGF23 and Klotho: the new cornerstones of phosphate/calcium metabolism].

Authors:  J Bacchetta; P Cochat; I B Salusky
Journal:  Arch Pediatr       Date:  2011-04-16       Impact factor: 1.180

5.  What's new in FGF23 research?

Authors:  Seiji Fukumoto
Journal:  Bonekey Rep       Date:  2012-07-04

6.  Effect of paricalcitol on circulating parathyroid hormone in X-linked hypophosphatemia: a randomized, double-blind, placebo-controlled study.

Authors:  Thomas O Carpenter; Elizabeth A Olear; Jane H Zhang; Bruce K Ellis; Christine A Simpson; David Cheng; Caren M Gundberg; Karl L Insogna
Journal:  J Clin Endocrinol Metab       Date:  2014-07-16       Impact factor: 5.958

Review 7.  Novel bone metabolism-associated hormones: the importance of the pre-analytical phase for understanding their physiological roles.

Authors:  Giovanni Lombardi; Mosè Barbaro; Massimo Locatelli; Giuseppe Banfi
Journal:  Endocrine       Date:  2017-02-08       Impact factor: 3.633

8.  Serum calcitriol levels in a patient with X-linked hypophosphatemia complicated by autosomal dominant polycystic kidney disease.

Authors:  Satomi Kajita; Takehisa Yamamoto; Naoko Tsugawa; Hirohumi Nakayama; Takuo Kubota; Toshimi Michigami; Keiichi Ozono
Journal:  CEN Case Rep       Date:  2016-10-22

9.  Iron and fibroblast growth factor 23 in X-linked hypophosphatemia.

Authors:  Erik A Imel; Amie K Gray; Leah R Padgett; Michael J Econs
Journal:  Bone       Date:  2013-12-08       Impact factor: 4.398

10.  Short-term Variability of Vitamin D-Related Biomarkers.

Authors:  Pamela L Lutsey; Christina M Parrinello; Jeffrey R Misialek; Andy N Hoofnagle; Clark M Henderson; Thomas J Laha; Erin D Michos; John H Eckfeldt; Elizabeth Selvin
Journal:  Clin Chem       Date:  2016-09-30       Impact factor: 8.327

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.